Announcements Trials
Browse Landscape

Phase

Phase 2 37Phase 3 6Phase 1/2 5Phase NA 3Phase 4 3Phase 2/3 3

Status

Recruiting 11Unknown 7Not yet recruiting 5Completed 2Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 4Other solid neoplasm 1

Conditions

Solid Tumor 1Pancreatic Cancer Resectable 1Pancreatic Cancer Metastatic 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 14Injections 13Drug Therapy 10Gemcitabine 9toripalimab 8venetoclax 7Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7Carboplatin 7pembrolizumab 6irinotecan sucrosofate 6Temozolomide 6HMPL-013 6tislelizumab 5sintilimab 5fludarabine 5N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5Fluorouracil 5Etoposide 5Cisplatin 5Biopsy 5osimertinib 4lenvatinib 4Rituximab 4Radiotherapy 4Pemetrexed 4Paclitaxel 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Not yet recruiting × sintilimab × Clear all
NCT07612137 2026-05-28

Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Not yet recruiting
282 enrolled
Other solid neoplasm

Solid Tumor

NCT07522411 2026-04-13

Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma

Tongji Hospital

Phase 1/2 Not yet recruiting
100 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT06888648 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy for Advanced Pancreatic Cancer.

Zhejiang University

Phase 1/2 Not yet recruiting
30 enrolled
Gastrointestinal

Pancreatic Cancer Metastatic

NCT06888674 2025-03-21

Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.

Zhejiang University

Phase 1/2 Not yet recruiting
60 enrolled
Gastrointestinal

Pancreatic Cancer Resectable

NCT06195670 2024-01-08

Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC

Zhejiang Cancer Hospital

Phase 1/2 Not yet recruiting
220 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡